Page 175 - CW E-Magazine (17-9-2024)
P. 175

Special Report                                                                   Special Report


 from India was banned in the first  decreases, India should relook at  C1 chemistry and their recent   are taken to boost this industry by  capabilities and properties. Although  that can improve transparency and
 half of 2020.  establishing large-scale  fermentation  importance in pharma industry  technological  interventions.  By  secondary in nature, their addition  collaboration between academia and
 facilities.  In India, there is need to develop   bringing new fermentation strains,  leads to significant enhancement in  the industry.
 Some measures have been taken   the chemicals and intermediates for   CRISPR technologies and provid-  performance of drugs through opti-
 to develop new technologies which   Incidentally, the  API sector has  pharma industry using the stable   ing special incentives, this industry  mum bioavailability, increased disinte-  In order to evaluate the best
 could enable producers to be price  been identifi ed as one of the 18 highly  and abundant one carbon molecules   can  be  revived  in 2-3  years.  There  gration, solubility, absorption, etc.  approach to a new collaboration, it is
 competitive.   polluting industries in India by the  such as methane, methanol, carbon   are specialized laboratories like IM-  in the final dosage form. Not only in  useful to consider examples of exist-
 Pollution Control Board. At present,  monoxide, and carbon dioxide.   TECH, which could play major role  performance, pharmaceutical exci-  ing successful partnerships between
 The public sector research labora-  every time a company intends to  Although there are many challenges   in these activities.  pients also help smooth handling of  academia and  API manufacturing
 tories  under  the  CSIR  network  have  make a change in the product mix, it  in the exploitation of the versatile C1   drugs during automated manufactur-  industry.
 been tasked with the development of  needs a fresh approval with the pro-  building blocks, it has the potential   Interventions for indigenous manu-  ing of final formulations.
 new, green and cost-effective tech-  cess taking as long as four months.  to  generate  various  acids,  esters,   facturing  The drive to transfer knowledge
 nologies for the production of APIs.  And for production or addition of  lactones, aromatics, acetic anhydride,   Roughly 50% of all APIs imported   Good capacity exists in India to  and innovation from academia to in-
 equipment, it could take eight months  ethylene glycol, methyl methacrylate,   into India feature on the National List  cater to some of the requirements of  dustry is increasingly fi erce, but fund-
 Adoption of technology as compared   or even more – again a deterrent for  methyl formate, etc. – all used in the   of Essential Medicines (NLEM), sig-  domestic formulations market. How-  ing restrictions and ongoing miscom-
 to global counterparts  API manufacturers.  pharma industry.   nalling the immediate need for self-  ever, most of this capacity is aimed  munications between  the  two  sides
 Since the 1980s, China has in-  reliance. Various Task  Forces  have  at fulfilling the requirements of  can hamper these attempts. Universi-
 vested signifi cantly to improve tech-  COVID API Mission by DSIR (CSIR)  Future production technologies for   pointed towards the importance of re-  domestic and non-regulated markets.  ties will have to provide strong leaders
 nological capabilities, especially in   Council of Scientifi c & Industrial  bulk and fine chemicals  building the API industry for national  Those players who are interested in  with an understanding of business to
 fermentation processes and common  Research (CSIR) with other labora-  There are several factors beyond   security, access to affordable medi-  high quality products with bioequiva-  negotiate such collaborations, and an
 utility programs. India lost large  tories  has  developed 25cost-effective   process technology that make manu-  cines, and export earnings. Of the 53  lence  studies  (BCS  2  &  4)  still  use  environment of mutual accountability
 volumes of fermentation-based  API  technologies using locally available  facturing APIs viable and attractive.   drugs, which were given special impe-  imported products.  must be nurtured. One of the biggest
 business including Pen G and 7-ACA  chemicals for the production of APIs  Over last few decades pharmaceuti-  tus recently by the DoP, 26 could be   challenges  to  academics  is  fi nding
 to China compelled by the availabi-  under  COVID  API Mission and is  cal processes have been developed   made without any biotechnological  Industry-academia engagement  the right, trustworthy partner to com-
 lity of low-cost energy, cluster-based  in the process  of transferring the  using chemistry in isolation and has   interventions. For India, a leader in   Collaboration between industry  mercialize a technology which may
 manufacturing approach and availabi-  technologies to industries.  neglected the engineering point of   organic chemistry and allied areas,  and academia can promote innova-  have been in development for years.
 lity of cheaper raw materials.  To   view. As a result, highly sub-optimal   these will be a ‘low hanging fruit’.  tion and growth in technology.  A mutual appreciation for the value
 provide an additional boost to the  Issues, challenges & opportunities   processes have been implemented with   Industry partnerships are  instrumental  of an innovation between industry
 pharma manufacturing capability,  to fill the technology gap  some great chemistry approaches. This   A detailed analysis of these 26  in advancing research and creating  a  and academic partners in API manu-
 China offers subsidies for effluent   makes a process unviable beyond   APIs, reveals that more than 50% of  skilled workforce.  facturing is needed.
 treatment  plants,  loans  at  low  in-  Availability of basic chemicals  a certain time. It is necessary to   KSMs for these APIs are not avail-
 terest rate,  and  tax  holidays.  As  a   Fluorine, chlorine, bromine and  have a unifi ed and highly networked   able in India and are being imported.   Collaborations with institutions  Policy recommendations
 result, China has been able to host  iodine form an important group of  approach that allows chemistry and   For example, for the synthesis of  like National Institute of Pharma-
 complex multistep manufacturing  reactive elements, known as halo-  engineering developments to work   Dexamethasone and other steroidal  ceutical Education and Research  Support for adequate infrastructure
 plants, which produce APIs in large  gens. Chlorine chemistry is essential  together all along the process.  drugs, KSM like Diosgenin is mostly  (NIPER), Council of Scientific and   To boost manufacturing of APIs
 quantities  and  at a  much larger  to  the  vast  majority  of  top-selling   imported.  A simple intervention by  Industrial Research (CSIR) labs and  in  the  country,  it  is  necessary  for
 scale than their Indian counterparts.  pharmaceuticals. Similarly, fluorine  Fermentation technology  the government to encourage grow-  universities are needed to improve  the government to develop adequate
 Chinese fermentation tanks have  also plays an important role in the   India was once very strong in   ing of plants which produce Dios-  process technologies.  infrastructure and come out with in-
 5-10 times more capacity than  drug industry. In general, four out of  fermentation technology. But after   genin will be an easy way to acquire   centive schemes to encourage more
 average  Indian  tanks.  To  further  10 drugs require fl uorination. In fact,  the  Drug Price  Control  Order   self-reliance in cortico-steroid series   Academia  can  play  a  major  role  investors.  The  major  issue  facing
 improve  efficiency  and  reduce  idle  in recent years, a growing number of  (DPCO), which was initiated in 1995   of products. Similarly, encouraging  in fostering research in collaboration  API manufacturing units in the coun-
 capacity, in 2019, China launched  blockbuster drugs developed glob-  by the government, Indian compa-  bulk chemical industries to build  with industry. While there are more  try today is related to lack of infra-
 a new plan to develop 20 ‘shared  ally like analgesics, anaesthetics,  nies turned to China for imports,   capacities around petroleum refine-  than 200 academic institutions facili-  structure and lack of support from
 manufacturing platforms’ by 2022  antibiotics, anticancer agents, anti-  as  APIs were cheaper  there.  This   ries to produce aromatics will bring  tating research, rate of commerciali-  the government. Government sup-
 through strong innovation capabi-  viral drugs and anti-HIV treatments,  continued for 15-20 years and now   down the cost of some of the essen-  zation continues to be lower than  port  for  R&D  to  reduce  the  import
 lity.  These would be turned into  etc. contain fluorine atoms because  businesses are habituated.  tial chemicals.  desired.  Academia can complement  dependency of APIs is very low and
 ‘key drivers for high-quality growth’  they increase bioactivity of the API,   industry’s efforts by focusing on  should be enhanced.
 by 2025.  as well as improve its stability, dis-  Due to external factors influenc-  Pharmaceutical excipients  areas that are relevant from patient
 solvability,  and  bioavailability.  ing the supply of essential fermenta-  Pharmaceutical excipients are in-  servicing point of view which the  Revive fermentation technology
 As the power and labour cost dis-  There are large deposits of fluoride  tion products, such as antibiotics, it   active substances that are added to  industry can eventually commercia-  Fermentation skills in India are
 advantage between China and India  salts in China, compared to India.  is imperative that special measures   drug formulations to improve various  lize. There is a need to create forums  almost totally lost, except in the


 174  Chemical Weekly  September 17, 2024  Chemical Weekly  September 17, 2024                         175


                                      Contents    Index to Advertisers    Index to Products Advertised
   170   171   172   173   174   175   176   177   178   179   180